Association between serum magnesium concentration and metabolic syndrome, diabetes, hypertension and hyperuricaemia in knee osteoarthritis: a cross-sectional study in Hunan Province, China

Yilun Wang,1 Jie Wei,2 Chao Zeng,1 Tuo Yang,1 Hui Li,1 Yang Cui,3 Dongxing Xie,1 Bei Xu,1 Zhichen Liu,1 Jiatian Li,1 Shide Jiang,1 Guanghua Lei1

ABSTRACT

Objectives To examine the associations between serum magnesium (Mg) concentration with the prevalence of metabolic syndrome (MetS), diabetes mellitus (DM), hypertension (HP) and hyperuricaemia (HU) in patients with radiographic knee osteoarthritis (OA).

Methods The present study was conducted at the Health Management Center of Xiangya Hospital. Radiographic OA was evaluated for patients aged over 40 years with basic characteristics and blood biochemical assessment. Serum Mg concentration was measured using the chemiluminescence method. MetS, DM, HP and HU were diagnosed based on standard protocols. The associations between serum Mg concentration with MetS, DM, HP and HU were evaluated by conducting multivariable adjusted logistic regression.

Results A total of 962 patients with radiographic knee OA were included. Compared with the lowest quintile, the multivariable adjusted ORs and related 95% CIs of DM were 0.40 (95% CI 0.23 to 0.70, p<0.001), 0.33 (95% CI 0.18 to 0.60, p<0.001), 0.27 (95% CI 0.14 to 0.52, p<0.001) and 0.22 (95% CI 0.11 to 0.44, p<0.001) in the second, third, fourth and highest quintiles of serum Mg, respectively (p for trend<0.001); the multivariable adjusted ORs of HU were 0.33 (95% CI 0.19 to 0.59, p<0.001), 0.52 (95% CI 0.30 to 0.91, p=0.022) and 0.39 (95% CI 0.22 to 0.70, p=0.001) in the third, fourth and highest quintiles of serum Mg, respectively (p for trend<0.001); and the multivariable adjusted ORs of MetS were 0.59 (95% CI 0.36 to 0.94, p=0.027) in the second and 0.56 (95% CI 0.34 to 0.93, p=0.024) in the highest quintiles of serum Mg. However, the inverse association between serum Mg and the prevalence of MetS was non-linear (p for trend=0.067). There was no significant association between serum Mg and HP in patients with OA.

Conclusions The serum Mg concentration was inversely associated with the prevalence of MetS, DM and HU in patients with radiographic knee OA.

Level of evidence Level III, cross-sectional study.

INTRODUCTION

The association between osteoarthritis (OA) and metabolic diseases, especially metabolic syndrome (MetS)1 2 and diabetes mellitus (DM),3–5 has drawn increasing attention in the past few years. OA includes three specific phenotypes: metabolic OA, age-related OA and injury-related OA.6 A large number of studies have indicated that the prevalence of MetS,7–9 DM10–18 and hypertension (HP)7 9–13 19 20 is either higher in patients with OA or associated with OA. In addition, some other studies reported that MetS,21 22 DM23 24 and HP21 22 are risk factors of OA progression. Thus, it appears necessary to pay more attention and adopt appropriate measures...
to reduce the high prevalence of metabolic diseases in patients with OA, which also seems to be beneficial in delaying OA progression.

Serum magnesium (Mg), one of the most important micronutrients for human health, has been reported to be negatively associated with MetS,25–29 DM30–38 and HP39–41 by lots of studies. Meanwhile, our previous study showed an inverse association between serum Mg and hyperuricaemia (HU).42 However, to the best knowledge of the authors, there is not yet a study examining the association between the serum Mg concentration and the aforementioned metabolic diseases (MetS, DM, HP and HU) in patients with OA. On the other hand, we have previously shown that the serum Mg concentration may be inversely associated with radiographic knee OA.43 Therefore, we speculate that the prevalence of MetS, DM, HP and HU in patients with OA may be reduced by elevating the level of serum Mg, which can in turn delay OA progression. Thus, the objective of the present study was to examine the associations between the serum Mg concentration with the prevalence of MetS, DM, HP and HU in patients with OA. It was hypothesised that serum Mg concentration was inversely associated with these diseases.

METHODS

Study population

The present study was conducted at the Health Management Center of Xiangya Hospital between October 2013 and November 2014. The study design has been published previously.42–46 Registered nurses were engaged to interview all participants during the examination using a standard questionnaire, with the purpose to collect information on demographic characteristics and health-related habits. Participants were selected based on the following inclusion criteria: (1) 40 years old or above; (2) undergoing weight-bearing bilateral anteroposterior radiography of the knee, and diagnosed with knee OA according to the Kellgren-Lawrence (K-L) radiographic atlas (knee joint was graded K-L 2 or above); (3) availability of all basic characteristics, including age, gender, Body Mass Index (BMI) and blood pressure; (4) availability of biochemical test results, including serum Mg concentration; (5) availability of information related to the living habits, including education background, activity level, smoking, drinking and medication status. Initially, the present cross-sectional study retrieved 1820 patients with radiographic knee OA aged over 40 years who exhibited sound basic characteristics and required blood biochemical assessment (including serum Mg concentration). Among them, 962 patients offered demographic characteristics and health-related habits and were finally included in this study.

Blood biochemistry

All blood samples were drawn after a 12-hour overnight fast and were kept at 4°C until analysis. Blood tests were undertaken using the Beckman Coulter AU 5800 (Beckman Coulter, Brea, California, USA). The inter-assay and intra-assay coefficients of variation were tested at both low concentrations (2.5 mmol/L for glucose, 118 μmol/L for uric acid and 0.60 mmol/L for serum Mg) and high concentrations (6.7 mmol/L for glucose, 472 μmol/L for uric acid and 1.00 mmol/L for serum Mg) of standard human samples. The intra-assay coefficients of variation were 0.98% (2.5 mmol/L) and 1.72% (6.7 mmol/L) for glucose, 1.39% (118 μmol/L) and 0.41% (472 μmol/L) for uric acid, and 1.86% (0.60 mmol/L) and 1.65% (1.00 mmol/L) for serum Mg, respectively. The inter-assay coefficients of variation were 2.45% (2.5 mmol/L) and 1.46% (6.7 mmol/L) for glucose, 1.40% (118 μmol/L) and 1.23% (472 μmol/L) for uric acid, and 1.87% (0.60 mmol/L) and 1.70% (1.00 mmol/L) for serum Mg, respectively.

Assessment of other exposures

Blood pressure was measured by an electronic sphygmomanometer. The weight and height of each subject were measured respectively to calculate the BMI. Information on the average frequency of physical activity (never, one to two times per week, three to four times per week, five times and above per week) and average duration of physical activity (less than half an hour, half an hour to 1 hour, 1 to 2 hours, more than 2 hours) were collected through survey questionnaire. The smoking, alcohol drinking and medication status were collected during the face-to-face interview.

Assessment of MetS, DM, HP and HU

MetS was diagnosed based on the Chinese Diabetes Society criteria,47–49 which requires meeting at least three of the following four items: (1) BMI ≥25 kg/m²; (2) fasting plasma glucose ≥6.1 mmol/L or diagnosed DM; (3) systolic blood pressure (BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg, or treatment of previously diagnosed HP; (4) triglycerides ≥1.7 mmol/L and/or high-density lipoprotein (HDL) cholesterol <0.9 mmol/L in men or <1.0 mmol/L in women, or treatment for this lipid abnormality. Subjects with fasting glucose ≥7.0 mmol/L or currently undergoing drug treatment for blood glucose control were regarded as patients with DM, and subjects with systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg or currently undertaking antihypertensive medication were regarded as patients with HP. HU was defined as uric acid ≥360 μmol/L for men and ≥300 μmol/L for women or currently undergoing drug treatment for uric acid control.

Statistical analysis

The continuous data were expressed as mean with SD, and the category data were expressed in percentage. Differences in continuous data were evaluated by one-way classification analysis of variance (normally distributed data) or Kruskal-Wallis H test (non-normally distributed data), while differences in category data were assessed by
the χ² test. The serum Mg was classified into five categories based on the quintile distribution: ≤0.85, 0.86–0.89, 0.90–0.92, 0.93–0.96 and 0.97–1.00 mmol/L. The prevalence of MetS, DM, HP and HU in each quintile of serum Mg in patients with OA was assessed by scatter plots.

Logistic regression was conducted to calculate the ORs with 95% CIs for the associations between serum Mg and MetS, DM, HP and HU. Specifically, model 1 was adjusted by covariates of age (continuous data) and gender (male, female). Then, model 2 was adjusted by additional covariates of BMI (continuous data), educational level (high school or above, lower than high school), smoking status (yes, no), alcohol drinking status (yes, no), HP (yes, no) and dyslipidemia (yes, no) on the basis of model 1. Dyslipidemia was defined as triglycerides ≥1.7 mmol/L and/or HDL cholesterol <0.9 mmol/L in men or <1.0 mmol/L in women, or defined as triglycerides, HDL cholesterol, activity level (continuous data), alcohol drinking status (yes, no), HP (yes, no), DM (yes, no) and dyslipidemia (yes, no) on the basis of model 1. Dyslipidemia was adjusted for the association between serum Mg and DM, HP and HU. Specifically, model 1 was adjusted for the association between serum Mg and MetS, DM, HP and HU. For example, BMI, HP and dyslipidemia were adjusted for the association between serum Mg and DM, but not for the association between serum Mg and MetS, simply because MetS was diagnosed based on BMI, HP and dyslipidemia status. Model 3 was established based on model 2, with adjustment of an additional covariate, estimated glomerular filtration rate (eGFR). eGFR (continuous data) was calculated from the Chronic Kidney Disease Epidemiology Collaboration equation. All covariates in the present study were chosen referring to some of the previous similar studies. Tests for linear trends were conducted based on logistic regression using a median variable of Mg concentration in each category.

Scatter plots were plotted using R V.3.4.4. Other data analyses were performed using SPSS V.17.0; p value ≤0.05 was considered to be statistically significant. All tests were two tailed.

Patient and public involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design or implementation of the study. There were no plans to disseminate the results of the research to study participants.

RESULTS

A total of 962 subjects (377 women, accounting for 39.2%) were included in the present cross-sectional study. The characteristics of the study population according to quintiles of serum Mg are presented in table 1. The mean age of the subjects was 54.9±7.6 years. The overall prevalence of MetS, DM, HP and HU in patients with OA were 21.4%, 12.0%, 38.5% and 18.3%, respectively. Significant differences were observed across the quintiles of serum Mg for fasting glucose, as well as the prevalence of DM and HU.

The prevalence of MetS in each quintile of serum Mg in patients with OA is shown in figure 1A. The outcomes of multivariable adjusted associations between MetS and serum Mg concentration are shown in table 2. Compared with the lowest quintile, the age–gender adjusted ORs (model 1) suggested significant decreased prevalence of MetS in the second (OR 0.61, 95% CI 0.38 to 0.97, p=0.038) and the highest (OR 0.59, 95% CI 0.36 to 0.96, p=0.035) quintiles of serum Mg; the multivariable adjusted ORs (model 2) also suggested significant decreased prevalence of MetS in the second (OR 0.60, 95% CI 0.37 to 0.96, p=0.035) and the highest (OR 0.61, 95% CI 0.37 to 0.99, p=0.047) quintiles. The sensitivity analysis, by adding eGFR into model 2, also reached similar results—significant lower prevalence of MetS in the second (OR 0.59, 95% CI 0.36 to 0.94, p=0.027) and the highest quintiles (OR 0.56, 95% CI 0.34 to 0.93, p=0.024) compared with the reference quintile of serum Mg. No clear trend was evident in the third and fourth quintiles of serum Mg. The p values for trend were 0.090 (model 1), 0.120 (model 2) and 0.067 (model 3), respectively.

Figure 1B shows the prevalence of DM in each category of serum Mg in patients with OA. Table 3 illustrates the multivariable adjusted relations between serum Mg and DM in patients with OA. Both the age–gender adjusted OR values (model 1) and the multivariable adjusted OR values (model 2) suggested a strong inverse association between serum Mg and DM. The age–gender adjusted ORs for the prevalence of DM were 0.38 (95% CI 0.22 to 0.66, p=0.001), 0.34 (95% CI 0.19 to 0.61, p<0.001), 0.29 (95% CI 0.15 to 0.55, p<0.001) and 0.20 (95% CI 0.10 to 0.40, p<0.001) in the second, third, fourth and fifth quintiles of serum Mg, respectively, and the p value for trend was <0.001. The multivariable adjusted ORs for the prevalence of DM were 0.40 (95% CI 0.23 to 0.70, p=0.001), 0.32 (95% CI 0.18 to 0.59, p<0.001), 0.26 (95% CI 0.13 to 0.50, p<0.001) and 0.21 (95% CI 0.11 to 0.42, p<0.001) in the second, third, fourth and fifth quintiles of serum Mg, respectively, and the p value for trend was <0.001. The sensitivity analysis, by adding eGFR into model 2, showed similar results—significant lower prevalence of DM in the second (OR 0.40, 95% CI 0.23 to 0.70, p=0.001), third (OR 0.33, 95% CI 0.18 to 0.60, p<0.001), fourth (OR 0.27, 95% CI 0.14 to 0.52, p<0.001) and highest quintiles (OR 0.22, 95% CI 0.11 to 0.44, p<0.001) compared with the reference quintile of serum Mg, and the p value for trend was <0.001.

The prevalence of HP in each quintile of serum Mg in patients with OA is depicted in figure 1C. The multivariable adjusted relations between serum Mg and HP in patients with OA are illustrated in table 4. According to both the age–gender adjusted ORs (model 1) and the multivariable adjusted ORs (model 2), there was no significant association between serum Mg and HP, and the p values for trend were 0.929 and 0.377, respectively. The sensitivity analysis, by adding eGFR into model 2, reached the same results.

The prevalence of HU in each category of serum Mg in patients with OA is shown in figure 1D. The multivariable adjusted relations between serum Mg and
HU in patients with OA are illustrated in table 5. Both the age–gender adjusted OR values (model 1) and the multivariable adjusted OR values (model 2) suggested significant decreased prevalence of HU in the third quintile (age–gender adjusted OR 0.44, 95% CI 0.26 to 0.75, p=0.002; multivariable adjusted OR 0.58, 95% CI 0.22 to 0.67, p=0.001) and fifth quintile (age–gender adjusted OR 0.51, 95% CI 0.30 to 0.85, p=0.010; multivariable adjusted OR 0.50, 95% CI 0.29 to 0.87, p=0.013) compared with the lowest quintile of serum Mg, and the p values for trend were 0.008 and 0.006, respectively. The sensitivity analysis, by adding eGFR into model 2, showed similar outcomes—significant lower prevalence of HU in the third (OR 0.33, 95% CI 0.19 to 0.59, p<0.001), fourth (OR 0.52, 95% CI 0.30 to 0.91, p=0.022) and highest quintiles (OR 0.39, 95% CI 0.22 to 0.70, p=0.001) compared with the reference quintile of serum Mg, and the p value for trend was <0.001.

**DISCUSSION**

The results of this study suggested that the serum Mg concentration was negatively associated with the prevalence of MetS, DM and HU in subjects with radiographic knee OA. To control potential confounders, several covariates including characteristics, living habits and underlying diseases were selected, and even the eGFR was added into the multivariable logistic regression models to eliminate the influence of renal function on Mg excretion. The reverse associations mentioned above remained significant after adjustments of these confounders. However, the association between serum Mg and the prevalence of MetS was non-linear, with no clear trend in the third and fourth quintiles of serum Mg. Moreover, the negative association between serum Mg and the prevalence of HP was not observed in patients with radiographic knee OA.

Mg, the fourth most abundant cation in the human body and the second most profuse intracellular cation, is a metallic cofactor for over 300 enzymatic reactions. It appears to play an important role in glucose metabolism and insulin homoeostasis, which are both highly correlated with metabolic diseases, especially MetS and DM. The mechanisms involved in Mg deficiency in patients with MetS, DM and HU are probably multifactorial. The most important factor may be insulin resistance, as Mg is essential for insulin action and is a critical cofactor for several enzymes in carbohydrate metabolism, which is important for the phosphorylation reactions of
tyrosine kinase in the insulin receptor. Of course, it is necessary to highlight the fact that insulin can also induce Mg excretion and produce a significant decline of plasma Mg through ion exchange. Thus, there seems to be a vicious circle between Mg deficiency and insulin resistance.

Other potential mechanisms include glucose transportation, oxidative stress and inflammatory cytokines.

### Figure 1
Prevalence of metabolic syndrome (MetS) (A), diabetes mellitus (DM) (B), hypertension (HP) (C) and hyperuricaemia (HU) (D) in each quintile of serum Mg in patients with radiographic knee OA. The figures above present the prevalence of MetS (A), DM (B), HP (C) and HU (D) among the 962 patients with OA under different quintiles of serum Mg levels. The horizontal axis denotes the serum Mg level, and the vertical axis indicates whether a subject is diagnosed with the specific disease: (+), disease; (−), no disease. The solid grey lines represent the boundaries in between the five quintiles of serum Mg levels. The red and black spots represent the prevalence of diseases and no diseases at each serum Mg level, respectively. The darker the colour of a spot, the more patients with OA there are at the corresponding concentration.

### Table 2
Multivariable adjusted relations of serum Mg and MetS in patients with OA (n=962)

| Quintiles of serum Mg | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P for trend |
|-----------------------|-------------|----|----|----|--------------|------------|
| Median Mg concentration (mmol/L) | 0.82 | 0.87 | 0.91 | 0.94 | 0.99 | – |
| Participants (n) | 200 | 215 | 190 | 168 | 189 | – |
| MetS (%) | 26.5 | 17.7 | 25.8 | 19.6 | 17.5 | – |
| Model 1* | 1.00 (reference) | 0.61 (0.38 to 0.97) | 0.97 (0.61 to 1.52) | 0.69 (0.42 to 1.14) | 0.59 (0.36 to 0.96) | 0.090 |
| P values | – | 0.038 | 0.881 | 0.150 | 0.035 | – |
| Model 2* | 1.00 (reference) | 0.60 (0.37 to 0.96) | 1.00 (0.63 to 1.57) | 0.70 (0.42 to 1.15) | 0.61 (0.37 to 0.99) | 0.120 |
| P values | – | 0.035 | 0.985 | 0.160 | 0.047 | – |
| Model 3* | 1.00 (reference) | 0.59 (0.36 to 0.94) | 0.95 (0.60 to 1.51) | 0.67 (0.40 to 1.10) | 0.56 (0.34 to 0.93) | 0.067 |
| P values | – | 0.027 | 0.830 | 0.114 | 0.024 | – |

Data are adjusted OR (95% CI), unless otherwise indicated.

*Model 1 was adjusted for age (continuous data) and gender (male, female); model 2 was adjusted for age (continuous data), gender (male, female), educational level (high school or above, lower than high school), smoking status (yes, no), activity level (continuous data) and alcohol drinking status (yes, no); model 3 was adjusted based on model 2, with additional factor of estimated glomerular filtration rate (continuous data).

MetS, metabolic syndrome; Mg, magnesium; n, number; OA, osteoarthritis.
Wang Y, et al. BMJ Open 2018;8:e019159. doi:10.1136/bmjopen-2017-019159

Open access

and cellular calcium homoeostasis.\textsuperscript{55} Mg is an essential cofactor of the high-energy phosphate-bound enzymatic pathways involved in the modulation of glucose transport across cell membranes.\textsuperscript{57} It also plays a role in the mechanisms of cellular antioxidant defence.\textsuperscript{64} The oxidative stress, defined as a persistent imbalance between the excessive production of reactive oxygen species and/or defects in antioxidant defence, has been implicated in the pathogenesis of diabetic complications.\textsuperscript{57} Moreover, low serum Mg levels are strongly related to elevated serum concentrations of both tumour necrosis factor alpha and C reactive protein (CRP).\textsuperscript{65} suggesting that Mg deficiency may contribute to the development of low-grade chronic inflammation syndrome and the development of glucose metabolic disorders through the former pathway. In addition, lower Mg concentration can enhance calcium-mediated vasoconstriction, blunt cardiac and smooth muscle relaxation, and thus contribute to BP elevation.\textsuperscript{55} However, the decreased serum calcium concentration in patients with radiographic knee OA may weaken the association between Mg and HP.\textsuperscript{66}

Meta\textsuperscript{21 22} and DM\textsuperscript{4 23 24} were reported to be the risk factors of OA progression. Moreover, serum Mg level has been proven to be significantly associated with CRP concentration,\textsuperscript{27 67–69} and higher CRP might serve as a prediction factor for OA progression.\textsuperscript{70 71} Thus, OA

Table 3  Multivariable adjusted relations of serum Mg and DM in patients with OA (n=962)

| Quintiles of serum Mg | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P for trend |
|-----------------------|-------------|----|----|----|--------------|------------|
| Median Mg concentration (mmol/L) | 0.82 | 0.87 | 0.91 | 0.94 | 0.99 | – |
| Participants (n) | 200 | 215 | 190 | 168 | 189 | – |
| DM (%) | 23.5 | 10.7 | 10.0 | 8.3 | 6.3 | – |
| Model 1* | 1.00 (reference) | 0.38 (0.22 to 0.66) | 0.34 (0.19 to 0.61) | 0.29 (0.15 to 0.55) | 0.20 (0.10 to 0.40) | <0.001 |
| P values | – | <0.001 | <0.001 | <0.001 | <0.001 | – |
| Model 2* | 1.00 (reference) | 0.40 (0.23 to 0.70) | 0.32 (0.18 to 0.59) | 0.26 (0.13 to 0.50) | 0.21 (0.11 to 0.42) | <0.001 |
| P values | – | <0.001 | <0.001 | <0.001 | <0.001 | – |
| Model 3* | 1.00 (reference) | 0.40 (0.23 to 0.70) | 0.33 (0.18 to 0.60) | 0.27 (0.14 to 0.52) | 0.22 (0.11 to 0.44) | <0.001 |
| P values | – | <0.001 | <0.001 | <0.001 | <0.001 | – |

Data are adjusted OR (95% CI), unless otherwise indicated.
*Model 1 was adjusted for age (continuous data) and gender (male, female); model 2 was adjusted for age (continuous data), Body Mass Index (continuous data), gender (male, female), educational level (high school or above, lower than high school), smoking status (yes, no), activity level (continuous data), alcohol drinking status (yes, no), hypertension (yes, no) and dyslipidemia (yes, no); model 3 was adjusted based on model 2, with additional factor of estimated glomerular filtration rate (continuous data).

Table 4  Multivariable adjusted relations of serum Mg and HP in patients with OA (n=962)

| Quintiles of serum Mg | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P for trend |
|-----------------------|-------------|----|----|----|--------------|------------|
| Median Mg concentration (mmol/L) | 0.82 | 0.87 | 0.91 | 0.94 | 0.99 | – |
| Participants (n) | 200 | 215 | 190 | 168 | 189 | – |
| HP (%) | 40.0 | 33.5 | 37.4 | 42.3 | 40.2 | – |
| Model 1* | 1.00 (reference) | 0.71 (0.47 to 1.06) | 0.83 (0.54 to 1.25) | 1.00 (0.66 to 1.54) | 0.89 (0.59 to 1.35) | 0.929 |
| P values | – | 0.095 | 0.368 | 0.987 | 0.582 | – |
| Model 2* | 1.00 (reference) | 0.77 (0.50 to 1.19) | 0.89 (0.57 to 1.39) | 1.10 (0.70 to 1.74) | 1.08 (0.69 to 1.68) | 0.377 |
| P values | – | 0.245 | 0.608 | 0.686 | 0.744 | – |
| Model 3* | 1.00 (reference) | 0.77 (0.50 to 1.19) | 0.88 (0.56 to 1.38) | 1.09 (0.68 to 1.72) | 1.05 (0.67 to 1.65) | 0.434 |
| P values | – | 0.235 | 0.574 | 0.727 | 0.818 | – |

Data are adjusted OR (95% CI), unless otherwise indicated.
*Model 1 was adjusted for age (continuous data) and gender (male, female); model 2 was adjusted for age (continuous data), Body Mass Index (continuous data), gender (male, female), educational level (high school or above, lower than high school), smoking status (yes, no), activity level (continuous data), alcohol drinking status (yes, no), diabetes (yes, no) and dyslipidemia (yes, no); model 3 was adjusted based on model 2, with additional factor of estimated glomerular filtration rate (continuous data).

HP, hypertension; Mg, magnesium; n, number; OA, osteoarthritis.
progression may be delayed by elevating the serum Mg level through reducing the prevalence of MetS and DM and decreasing the level of CRP. Above all, the present study indicated that the elevation of serum Mg level has the potential to reduce the prevalence of MetS, DM and HU in patients with knee OA and may delay the progression of knee OA. However, the specific mechanism needs to be further explored.

The present study has several strengths. First, this is the first study examining the associations between serum Mg and the prevalence of MetS, DM and HU in patients with radiographic knee OA. The results of this study will provide a new insight into the treatment of knee OA. Second, the multivariable logistical regression models were adjusted for a considerable number of potential confounding factors, which greatly improved the reliability of the results. Third, the kidney is the key organ in maintaining Mg homeostasis. This study conducted a sensitivity analysis by adding eGFR into multivariable logistic regression models, which showed that the reverse associations remained significant.

Limitations of the present study should also be admitted. The cross-sectional design precludes causal correlations, so further prospective studies and intervention trials should be undertaken to establish a causal association between serum Mg with the prevalence of MetS, DM, HP and HU in patients with radiographic knee OA. Since no previous research investigated such associations in patients with knee OA, the value of this study should not be blotted out by the cross-sectional nature. Another limitation of this study lies in the relatively small sample size, and thus, extensive high-quality researches based on a larger sample are needed. Moreover, the dietary intake of Mg in relation to the prevalence of MetS, DM, HP and HU was not assessed in the present study. Last but not the least, it is important to highlight that Mg is an intracellular ion; therefore, the serum Mg concentration must be considered as a poor indicator of body Mg content even though it has been used in many studies. However, blood Mg level is the second best indicator of body status.

CONCLUSIONS

The present study concluded that the serum Mg concentration was inversely associated with the prevalence of MetS, DM and HU in patients with radiographic knee OA.

Table 5 Multivariable adjusted relations of serum Mg and HU in patients with OA (n=962)

| Quintiles of serum Mg | P for trend |
|-----------------------|------------|
|                        | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P for trend |
| Median Mg concentration (mmol/L) | 0.82 | 0.87 | 0.91 | 0.94 | 0.99 | – |
| Participants (n) | 200 | 215 | 190 | 168 | 189 | – |
| HU (%) | 25.5 | 19.1 | 13.2 | 18.5 | 14.8 | – |
| Model 1* | 1.00 (reference) | 0.71 (0.44 to 1.14) | 0.44 (0.26 to 0.75) | 0.68 (0.41 to 1.14) | 0.51 (0.30 to 0.85) | 0.008 |
| P values | – | 0.157 | 0.002 | 0.144 | 0.010 | – |
| Model 2* | 1.00 (reference) | 0.73 (0.45 to 1.20) | 0.38 (0.22 to 0.67) | 0.59 (0.35 to 1.02) | 0.50 (0.29 to 0.87) | 0.006 |
| P values | – | 0.210 | 0.001 | 0.058 | 0.013 | – |
| Model 3* | 1.00 (reference) | 0.68 (0.41 to 1.14) | 0.33 (0.19 to 0.59) | 0.52 (0.30 to 0.91) | 0.39 (0.22 to 0.70) | <0.001 |
| P values | – | 0.142 | <0.001 | 0.022 | 0.001 | – |

Data are adjusted OR (95% CI), unless otherwise indicated.

*Model 1 was adjusted for age (continuous data) and gender (male, female); model 2 was adjusted for age (continuous data), Body Mass Index (continuous data), gender (male, female), educational level (high school or above, lower than high school), smoking status (yes, no), activity level (continuous data), alcohol drinking status (yes, no), hypertension (yes, no), diabetes (yes, no) and dyslipidemia (yes, no); model 3 was adjusted based on model 2, with additional factor of estimated glomerular filtration rate (continuous data). HU, hyperuricaemia; Mg, magnesium; n, number; OA, osteoarthritis.
REFERENCES

1. Zhuo Q, Yang W, Chen J, et al. Metabolic syndrome meets osteoarthritis. *Nat Rev Rheumatol* 2012;8:729–37.

2. Inoue R, Ishibashi Y, Tsuda E, et al. Increased prevalence of metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: results of a national survey. *J Clin Endocrinol Metab* 2014;99:3177–83.

3. Calvet J, Orellana C, Larroza M, et al. High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis. *Scand J Rheumatol* 2015;1–4.

4. Raham MM, Kopeca JA, Ciberj J, et al. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. *BMJ Open* 2013;3:e002624.

5. Inoue D, Ishibashi Y, Tsuda E, et al. Medical problems and risk factors of metabolic syndrome among radiographic knee osteoarthritis patients in the Japanese general population. *J Orthop Sci* 2011;16:704–9.

6. Hart DJ, Doyle DV, Spector TD. Association between metabolic syndrome and serum magnesium concentration and hyperuricemia. *Magnes Res* 1996;9:173–81.

7. Anagnostopoulos I, Zinzaras E, Alexiou I, et al. Association between metabolic syndrome, radiographic knee osteoarthritis and cardiovascular disease in a population health survey. *Atherosclerosis Risk in Communities Study*. *J Clin Epidemiol* 1995;48:927–40.

8. Shin D. Association between metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: results of a national survey. *J Clin Endocrinol Metab* 2014;99:3177–83.

9. Calvet J, Orellana C, Larroza M, et al. High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis. *Scand J Rheumatol* 2015;1–4.

10. Raham MM, Kopeca JA, Ciberj J, et al. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. *BMJ Open* 2013;3:e002624.

11. Inoue D, Ishibashi Y, Tsuda E, et al. Medical problems and risk factors of metabolic syndrome among radiographic knee osteoarthritis patients in the Japanese general population. *J Orthop Sci* 2011;16:704–9.

12. Hart DJ, Doyle DV, Spector TD. Association between metabolic syndrome and serum magnesium concentration and hyperuricemia. *Magnes Res* 1996;9:173–81.

13. Anagnostopoulos I, Zinzaras E, Alexiou I, et al. Association between metabolic syndrome, radiographic knee osteoarthritis and cardiovascular disease in a population health survey. *Atherosclerosis Risk in Communities Study*. *J Clin Epidemiol* 1995;48:927–40.

14. Calvet J, Orellana C, Larroza M, et al. High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis. *Scand J Rheumatol* 2015;1–4.

15. Raham MM, Kopeca JA, Ciberj J, et al. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. *BMJ Open* 2013;3:e002624.

16. Inoue D, Ishibashi Y, Tsuda E, et al. Medical problems and risk factors of metabolic syndrome among radiographic knee osteoarthritis patients in the Japanese general population. *J Orthop Sci* 2011;16:704–9.

17. Hart DJ, Doyle DV, Spector TD. Association between metabolic syndrome and serum magnesium concentration and hyperuricemia. *Magnes Res* 1996;9:173–81.

18. Anagnostopoulos I, Zinzaras E, Alexiou I, et al. Association between metabolic syndrome, radiographic knee osteoarthritis and cardiovascular disease in a population health survey. *Atherosclerosis Risk in Communities Study*. *J Clin Epidemiol* 1995;48:927–40.
45. Xie DX, Xiong YL, Zeng C, et al. Association between low dietary zinc and hyperuricaemia in middle-aged and older males in China: a cross-sectional study. BMJ Open 2015;5:e8637.

46. Wei J, Zeng C, Gong QY, et al. The association between dietary selenium intake and diabetes: a cross-sectional study among middle-aged and older adults. Nutr J 2015;14:18.

47. Expert panel on metabolic syndrome of Chinese Diabetes Society: recommendations on metabolic syndrome of Chinese Diabetes Society (Chinese). Chin J Diabetes 2004;14:156–61.

48. Pang C, Jia L, Hou X, et al. The significance of screening for microvascular diseases in Chinese community-based subjects with various metabolic abnormalities. PLoS One 2014;9:e97928.

49. Zhou H, Guo ZR, Yu LG, et al. Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract 2010;90:319–25.

50. Levey AS, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.

51. Joosten MM, Gansevoort RT, Mukamal KJ, et al. Magnesium deficiency and older U.S. women. Diabetes Care 2005;28:1175–81.

52. Grundy SM, Cleeman JI, Daniels SR, et al. Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension 2013;61:1161–7.

53. Cho MK, Bae YJ. Association of magnesium intake with high blood pressure in Korean adults: Korea National Health and Nutrition Examination survey 2007–2009. PLoS One 2015;10:e0130405.

54. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2016.

55. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.

56. Barbagallo M, Ganevsoo RT, Mukamal KJ, et al. Magnesium deficiency in insulin-resistant, diabetic, and hyper-metabolic syndrome X. Mol Aspects Med 2003;24(1–3):39–52.

57. Song Y, Ridker PM, Manson JE, et al. Magnesium intake, C-reactive protein and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005;28:1438–44.

58. Guerrero-Romero F, Rodriguez-Moran M. Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants. Arch Med Res 2005;36:250–7.

59. Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care 2005;28:1175–81.

60. Djurhuus MS, Skott P, Hether-Nielson O, et al. Insulin increases renal magnesium excretion: a possible cause of magnesium depletion in hyperinsulinaemic states. Diabet Med 1995;12:664–9.

61. Paolisso G, Sambato S, Passariello N, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia 1986;29:644–7.

62. Bonora E, Targher G, Zenere MB, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996;20:975–80.

63. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One 2011;6:e19901.

64. Kirilmaz B, Asgun F, Alioglu E, et al. High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens 2010;12:136–44.

65. Rodríguez-Moran M, Guerrero-Romero F. Elevated serum concentration of tumor necrosis factor-alpha is linked to low serum magnesium levels in the obesity-related inflammatory response. Magnes Res 2004;17:189–96.

66. Li H, Zeng C, Wei J, et al. Serum calcium concentration is inversely associated with radiographic knee osteoarthritis: a cross-sectional study. Medicine 2016;95:e2838.

67. Chacko SA, Song Y, Nathan L, et al. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care 2010;33:304–10.

68. Bo S, Durazzo M, Guidi S, et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 2006;84:1062–9.

69. Kim DJ, Xun P, Liu K, et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010;33:2604–10.

70. Spector TD, Hart DJ, Nandra D, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

71. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

72. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

73. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

74. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

75. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

76. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

77. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

78. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

79. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.

80. Smith JW, Martins TB, Gopez E, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.